Positive Results from Ph 2 BELLA Trial of Lifyorli, Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer Reported
“Our goal is to demonstrate our proprietary selective GR antagonists’ ability to benefit patients with a wide array of solid tumors, in combination with many different anti-cancer agents,” said Bill Guyer, Pharm.D., Corcept’s Chief Development Officer. “These results provide more evidence of GR antagonism’s versatility – in this case, of Lifyroli’s potential to benefit patients when combined with nab-paclitaxel and bevacizumab, whether or not bevacizumab had been included in a patient’s prior treatment regimen. We look forward to presenting the full BELLA Part A data next year.”
Share:
More News
“We’ve already seen what subcutaneous amivantamab may offer patients with head and neck cancer after their disease has progressed. Now, we see the potential impact of using this approach earlier in recurrent or metastatic disease,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. “Our
“Meaningful progress has been made in the treatment of pancreatic cancer and we are proud that Tumor Treating Fields therapy is one of the new options available to patients. However, advanced pancreatic cancer remains one of the most difficult cancers to treat,” said Uri Weinberg, MD, PhD, Chief Medical and
“We see anal cancer as the starting point for building a pelareorep plus checkpoint inhibitor platform across HPV-driven cancers,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Our survival data and recent FDA regulatory clarity give us a path to pursue registration in anal cancer while expanding into other HPV-associated
“Multiple myeloma is a chronic blood cancer that can reshape a person’s life. Patients deserve therapeutic options that are not only effective, but also support the realities of when, where and how they receive treatment,” said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology,